Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
31 May 2007Website:
http://amicusrx.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 57 min agoDividend
Analysts recommendations
Institutional Ownership
FOLD Latest News
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.07 per share a year ago.
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Simon Harford - CFO Ellen Rosenberg - Chief Legal Officer Conference Call Participants Ritu Baral - TD Cowen Anupam Rama - JP Morgan Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Joe Schwartz - Leerink Partners Dae Gon Ha - Stifel Dennis Ding - Jefferies Kristen Kluska - Cantor Fitzgerald Michael Riad - Morgan Stanley Gil Blum - Needham & Company Salveen Richter - Goldman Sachs Operator Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Third Quarter 2024 Financial Results Conference Call and Webcast.
The consensus price target hints at a 51.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2024.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amicus Therapeutics settled litigation with Teva, preventing a generic version of Galafold for Fabry Disease until 2037, ensuring revenue growth. Pombiliti + Opfolda approved for late-onset Pompe Disease, with potential label expansion to children and infants with successful studies, boosting market opportunity. Galafold sales grew 17% YoY to $110.8 million in Q2 of 2024, with full-year 2024 revenue growth guidance raised to 14%-18%.
Amicus stock gains on reaching a licensing deal with Teva, which ends their Galafold patent lawsuit.
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037 Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037
What type of business is Amicus Therapeutics?
Amicus Therapeutics, Inc. is a global biotechnology company dedicated to the discovery, development, and delivery of medicines for the treatment of rare diseases. Amicus Therapeutics, Inc. was registered in 2002, with its headquarters located in Philadelphia, Pennsylvania. The company's main product is Galafold, the first approved oral precision medicine for people living with Fabry disease and having genetically amenable variants. The drug is approved under the trade name Galafold in the United States, European Union, United Kingdom, and Japan, with several additional approvals and applications under review in multiple regions worldwide.
What sector is Amicus Therapeutics in?
Amicus Therapeutics is in the Healthcare sector
What industry is Amicus Therapeutics in?
Amicus Therapeutics is in the Biotechnology industry
What country is Amicus Therapeutics from?
Amicus Therapeutics is headquartered in United States
When did Amicus Therapeutics go public?
Amicus Therapeutics initial public offering (IPO) was on 31 May 2007
What is Amicus Therapeutics website?
https://amicusrx.com
Is Amicus Therapeutics in the S&P 500?
No, Amicus Therapeutics is not included in the S&P 500 index
Is Amicus Therapeutics in the NASDAQ 100?
No, Amicus Therapeutics is not included in the NASDAQ 100 index
Is Amicus Therapeutics in the Dow Jones?
No, Amicus Therapeutics is not included in the Dow Jones index
When was Amicus Therapeutics the previous earnings report?
No data
When does Amicus Therapeutics earnings report?
The next expected earnings date for Amicus Therapeutics is 28 February 2025